leadf
logo-loader
viewBiocept Inc

Biocept's newly split adjusted stock to begin trading on Nasdaq on September 8

The company's stockholders approved the share split at Biocept's 2020 annual meeting of stockholders

Biocept Inc -
Biocept is a diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma

Biocept Inc (NASDAQ:BIOC) announced that its common shares will begin trading on its new split-adjusted basis on the Nasdaq in New York at the opening bell on September 8.

It comes after the group's one-for-ten (ten shares combined and converted into one) reverse stock split which became effective at 5pm EST on September 4 this year.

The stock will continue to trade under the ticker 'BIOC'.

READ: Biocept says it has processed more than 20,000 COVID-19 specimens at its San Diego lab

The company's stockholders approved the share split at Biocept's 2020 annual meeting of stockholders. The aim was to increase the firm's share price to, among things, enable it to regain compliance with the US$1.00 minimum bid price requirement for the Nasdaq listing rules.

Biocept is a diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. It has recently added coronavirus (COVID-19) testing to support efforts to fight the pandemic.

On August 31, it told investors it had received more than 21,000 COVID-19 specimens and processed more than 20,000 to date using RT-PCR technology at its San Diego lab.

The company said it has distributed about 46,000 COVID-19 PCR specimen collection kits to-date and has around 34,000 additional collection kits assembled and available for immediate distribution.

The vast majority of COVID-19 test results were reported to healthcare providers within 48 hours of receipt of the specimen.

Biocept’s lab is a specialized, licensed molecular lab staff who have been trained in performing the COVID-19 testing.

Contact the author at giles@proactiveinvestors.com

Quick facts: Biocept Inc

Price: 4.43 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $59.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read